Search Results
Your search for ,foR matches 32412 pages
Showing 15951 - 16000An Early Love of Literature Gives Way to a Career in Breast Cancer Research for Jennifer K. Litton, MD
Breast cancer specialist Jennifer K. Litton, MD, was born and reared in Leominster, Massachusetts, a small city in the north central part of the state. “I went to parochial schools until seventh grade and then went on to high school in Worcester. Although I enjoyed science early on, I was...
James Allison, PhD, and Tasuku Honjo, MD, PhD, Win 2018 Nobel Prize in Physiology or Medicine
JAMES ALLISON, PHD, Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and Tasuku Honjo, MD, PhD, Distinguished Professor at the Kyoto University Institute for Advanced Study and Professor of Immunology and Genomic Medicine ...
Closing the Gender Divide in Preference for Palliative Care
Eight years ago, a survey of the preferences of Dutch patients with cancer for health care found that while gender was one aspect influencing how men and women approach cancer care, it was the most important, with men, generally, regarding most care aspects as less important than women. The study...
FDA Approves Dacomitinib for Metastatic Non–Small Cell Lung Cancer
ON SEPTEMBER 27, 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib tablets (Vizimpro) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution...
New Techniques in Intraoperative-Guided Imagery May Enhance Outcomes in Patients With Cancer
Primary treatment of most solid tumors includes surgical excision or radiation therapy, both of which require precise anatomic localization of the tumor as well as surrounding tissue and organs. If the targeting is too broad, unnecessary morbidity may occur to nearby structures, along with the...
FDA Approves Duvelisib for Adult Patients With Relapsed or Refractory Hematologic Malignancies
ON SEPTEMBER 24, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to duvelisib (Copiktra) for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib also received accelerated...
Pasi A. Jänne, MD, PhD, Receives ESMO Translational Research Award
THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has chosen Pasi A. Jänne, MD, PhD, to receive the ESMO Translational Research Award for his research contributions in lung cancer. Dr. Jänne is Director of the Lowe Center for Thoracic Oncology and Director of the Belfer Center for Applied Cancer...
ESMO Recognizes Tony S. Mok, MD, FRCPC, FASCO, With Lifetime Achievement Award
THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has recognized Tony S. Mok, MD, FRCPC, FASCO, with the ESMO Lifetime Achievement Award for his contributions in lung cancer. Dr. Mok, who is a Li Shu Fan Medical Foundation Endowed Professor and Chairman of the Department of Clinical Oncology at the ...
PCF Releases First National Report on Public Perception of Prostate Cancer in the United States
The Prostate Cancer Foundation (PCF) recently released the results of its first national public awareness report about risks, actions, and attitudes toward prostate cancer in the PCF 3P Report 2018: Public Perception of Prostate Cancer. Each year, even though more than three million men in...
Results From ECHELON-2: Brentuximab Vedotin in CD30-Expressing Peripheral T-Cell Lymphoma
The phase III ECHELON-2 clinical trial has met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) with brentuximab vedotin (Adcetris) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide,...
Immune Checkpoint Blockade and Tumor-Specific Vaccine for Incurable HPV16-Related Cancer
In a single-center phase II study reported in JAMA Oncology, Massarelli et al found combining tumor-specific vaccine and nivolumab (Opdivo) showed evidence of activity in incurable human papillomavirus (HPV) 16–related cancer. The therapeutic vaccine, ISA 101, induces HPV-specific T cells....
Lurbinectedin in BRCA-Mutated and Unselected Metastatic Breast Cancer
In a phase II study reported in the Journal of Clinical Oncology, Cruz et al found that the trabectedin (Yondelis) analog lurbinectedin was active in patients with metastatic breast cancer with germline BRCA mutations, with much lower activity in those without BRCA mutation or unknown mutation...
Dutch Study of Postoperative Outcomes With Screening- vs Nonscreening-Detected Colon and Rectal Cancers
In a Dutch study reported in JAMA Surgery, de Neree tot Babberich et al found that postoperative outcomes were better in patients with colon cancer, but not rectal cancer, detected vs not detected through the national fecal immunochemical test–based screening program. Study ...
Early PSA Testing Could Help Predict Prostate Cancer Among Black Men
In a study published by Preston et al in European Urology, researchers demonstrated that a baseline prostate-specific antigen (PSA) level obtained from black men between 40 and 60 years old may predict the future development of prostate cancer for years after testing. The study builds on ...
Small Study Shows Fecal Microbiota Transplantation May Help Restore Beneficial Bacteria in Patients With Cancer
Researchers have shown that autologous fecal microbiota transplantation may be a safe and effective way to help replenish beneficial gut bacteria in patients with cancer who require intense antibiotics during allogeneic hematopoietic stem cell transplantation. Their findings were published by Taur...
FDA Approves Expanded Use of Gardasil 9 to Include Individuals Aged 27 to 45
The U.S. Food and Drug Administration (FDA) has approved a supplemental application for recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil 9), expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and...
Atezolizumab Plus Chemotherapy in Previously Untreated Extensive-Stage Small Cell Lung Cancer
As reported at the recent International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer and in The New England Journal of Medicine by Horn et al, the phase III IMpower133 study has shown significant improvement in overall and progression-free survival with...
Neoadjuvant Paclitaxel With LCL161 in Localized Triple-Negative Breast Cancer
In a phase II study reported in the Journal of Clinical Oncology, Bardia et al evaluated the effects of adding an antagonist of inhibitor of apoptosis proteins (LCL161) to paclitaxel as neoadjuvant therapy in patients with localized triple-negative breast cancer who did or did not have a tumor...
In Vitro and Ex Vivo Activity of Gentian Violet in Cutaneous T-Cell Lymphoma
As reported in JAMA Dermatology, Wu and Wood found that the widely available nonprescription topical antimicrobial agent gentian violet has potent activity against cutaneous T-cell lymphoma (CTCL) in studies in vitro and ex vivo. The study involved high-throughput small molecule screening of 1,710...
FDA Grants Breakthrough Therapy Designation to Rucaparib in BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to rucaparib (Rubraca) monotherapy for the treatment of adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer who have received at least one prior androgen...
ASCP, CAP, and ASH Invite Public Comment on Lymphoma Guideline
With a focus on the pathology aspects of diagnosing lymphoma, the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), and the American Society of Hematology (ASH) are collaborating to develop an evidence-based clinical practice guideline for the workup of...
U.S. Spending on Antineoplastic Agents
In a study reported in the Journal of Oncology Practice, Hong et al found that the U.S. health-care system increased spending on antineoplastic agents from $26.8 billion in 2011 to $42.1 billion in 2016. The study was a retrospective, cross-sectional analysis of IQVIA (formerly QuintilesIMS)...
Lack of Clinical Trial Participation and Shorter Duration of Therapy Linked to Disease Relapse in AYAs With Leukemia
Despite survival gains for children diagnosed with acute lymphoblastic leukemia (ALL), adolescents and young adults (AYAs)—those between the ages of 15 and 39—diagnosed with the disease have seen only modest improvements in survival. A study by Wolfson et al in Cancer Epidemiology,...
Sex-Linked Differences in Cancer May Identify Specific Genetic Drivers, Predict Responses to Treatment
Analysis of male- and female-derived tumor samples revealed differences in prognostic biomarkers, genes that drive cancer, and in regulation of key pathways that may predict responses to treatment, according to results published in two studies in Cancer Research, one by Li et al and the other...
DNA Vaccine Leads to Immune Responses in HPV-Related Head and Neck Cancer in Small Study
A therapeutic vaccine may boost antibodies and T cells, helping them infiltrate human papillomavirus (HPV)-related head and neck cancer tumors. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with...
Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer
In a long-term follow-up of a phase I trial reported in JAMA Oncology, Emens et al found that single-agent atezolizumab (Tecentriq) produced enduring benefit in patients with metastatic triple-negative breast cancer after stable or responding disease and in first-line treatment. Study Details In...
Management of Clostridium difficile Infection in Children and Adolescents With Cancer and Pediatric HSCT Recipients
As reported in the Journal of Clinical Oncology by Diorio et al, an international panel has released a clinical practice guideline on prevention and treatment of Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation...
No Survival Benefit With Avelumab vs Docetaxel in Platinum-Treated, Advanced, PD-L1–Positive NSCLC
As reported in The Lancet Oncology by Barlesi et al, the phase III JAVELIN Lung 200 trial has shown no overall survival benefit with avelumab (Bavencio) vs docetaxel in patients with platinum pretreated programmed cell death ligand 1 (PD-L1)–positive advanced non–small cell lung cancer...
Updated ASCO Answers Fact Sheets for Your Practice
Be sure to check out these newly updated ASCO Answers fact sheets: Chronic Lymphocytic Leukemia Lung Cancer Melanoma Multiple Myeloma Pancreatic Cancer Prostate Cancer Thrombocytopenia When Cancer Spreads to the Bone These one-page (front and back) introductions include a topic overview; an...
ASCO Quality Training Program Reaches Over 100-Team Milestone; New 1-Day Option Now Available
As of August 2018, more than 100 teams from oncology practices around the United States and the world have participated in ASCO’s Quality Training Program (QTP). The QTP offers education and training for physician-led oncology teams. The program prepares teams of oncology providers to design,...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
How do patients really feel when they are in your care? What does it feel like to cure a cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? These are the personal topics explored in the candid and inspirational mini-podcast series, Your Stories:...
Cancer.Net: Trusted Information for Patients and Caregivers, Useful Tools for Providers
Cancer.Net is ASCO’s patient information website, hosting a wealth of information and resources for people diagnosed with cancer and their families and caregivers. With information on over 120 types of cancer, visitors to the site can find medical information, tips for treatment management,...
ASCO Analysis Finds Some Pharmacy Benefit Manager Practices May Erode Patient Access to Cancer Care
ASCO warns that some of the practices used by pharmacy benefit manager (PBM) companies could hinder patient access to timely, high-quality cancer care. While PBM practices may be intended to help control costs in cancer care, in a new position statement, ASCO describes a range of practices that...
How Do You Know What You Don’t Know?
In the world of modern medicine, with its constant stream of new information, it can be hard to keep up—especially when you already have a packed schedule. With so much new information to learn and absorb, and the need to prioritize your time, how do you know what you don’t know? Without...
Emerging Options and Sequencing Therapy in Relapsed Multiple Myeloma
Advances in the treatment of multiple myeloma have led to longer progression-free survival, but the majority of patients will still relapse despite newer treatments. A number of new drugs and combinations are under study in the hope of improving outcomes. “Multiple myeloma is a complex disease...
FDA Authorizes First Next-Generation Sequencing–Based Test to Detect Minimal Residual Disease in B-Cell ALL or Multiple Myeloma
The U.S. Food and Drug Administration (FDA) recently permitted marketing of the ClonoSEQ assay, a next-generation sequencing–based test for minimal residual disease in patients with B-cell acute lymphoblastic leukemia (ALL) or multiple myeloma. “At the FDA, we’re continuing to...
Study Shows Invasive Lung Cancer Surgery Can Lead to Long-Term Opioid Use
Patients treated with more invasive surgical techniques for early-stage non–small cell lung cancer (NSCLC) are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery ...
Addition of a CTLA-4–Targeted Therapy to a Checkpoint Inhibitor in Ovarian Cancer
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab (Yervoy), a monoclonal antibody that targets the protein receptor cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), to a regimen with the checkpoint inhibitor nivolumab (Opdivo) could improve response ...
More to Learn About Using PARP Inhibitors for Advanced Breast Cancer With Germline BRCA Mutation
Germline mutations in the breast cancer–susceptibility genes 1 and 2 (BRCA1/2) increase the risk for cancer due to an inability to repair DNA double-strand breaks, and about 5% of patients with unselected breast cancer carry a germline BRCA mutation.1 These DNA repair–deficient tumors are...
Risk of Late Venous Thromboembolism in Survivors of Childhood Cancer
In a report from the Childhood Cancer Survivor Study published in the Journal of Clinical Oncology, Madenci et al found that survivors of childhood cancer are at increased risk of late venous thromboembolism, with several factors increasing such risk. The study involved data from a...
Low- vs High-Dose Cisplatin Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
In an analysis of Veterans Affairs data reported in the Journal of the National Cancer Institute, Bauml et al found that weekly lower-dose cisplatin vs higher-dose cisplatin given every 3 weeks as part of concurrent definitive chemoradiotherapy may not adversely affect survival, while reducing...
Ovarian Function After Response-Adapted Treatment in Younger Women With Advanced Hodgkin Lymphoma
In a secondary analysis of the UK phase III RATHL trial reported in The Lancet Oncology, Anderson et al found that ovarian function recovery was affected by age and type of response-adapted therapy in women receiving treatment for advanced Hodgkin lymphoma. The analysis included 67 eligible...
Talazoparib Improves Progression-Free Survival in Advanced Breast Cancer With Germline BRCA Mutation
As reported in The New England Journal of Medicine by Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, the phase III EMBRACA trial has shown significantly improved progression-free survival with the poly (ADP-ribose) polymerase (PARP) inhibitor...
Lalan S. Wilfong, MD, on Metastatic Solid Tumors: Limiting Low-Value Care
Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.
Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome
On August 8, 2018, the CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody mogamulizumab-kpkc (Poteligeo) was approved for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.1,2 Supporting Efficacy Data The current...
Lauren P. Wallner, PhD, MPH, on Thyroid Cancer: Reducing Overtreatment With Radioactive Iodine
Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings from a population-based study, which showed that many patients believe they had no choice about whether or not to receive radioactive iodine, even though it often does not improve survival. There is a need, she says, ...
Targeting CCR4 in Cutaneous T-Cell Lymphoma: The MAVORIC Trial
The C-C chemokine receptor 4 (CCR4) is predominantly expressed in type 2 helper T (Th2) cells and regulatory T (Treg) cells.1 Under physiologic conditions and in response to its ligands, CCL17 (TARC) and CCL22 (MDC), CCR4 promotes T-cell migration to the skin.2 Of note, CCR4 is highly expressed in...
Angela M. Stover, PhD, on Patient-Reported Symptoms: Results From the STAR and PRO-TECT Trials
Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses study findings on ways to alert clinicians when patients signal symptoms such as pain or diarrhea that may be cause for concern (Abstract 158).
Mogamulizumab Improves Progression-Free Survival vs Vorinostat in Cutaneous T-Cell Lymphoma
As reported by Youn H. Kim, MD, of Stanford Cancer Institute, Stanford University School of Medicine, and colleagues in The Lancet Oncology, the phase III MAVORIC trial showed that the anti-C-C chemokine receptor 4 (CCR4) monoclonal antibody mogamulizumab (Poteligeo) significantly improved...
Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma
In the phase III RELEVANCE trial reported in The New England Journal of Medicine by Franck Morschhauser, MD, PhD, of The University of Lille, Centre Hospitalier Universitaire Lille, France, and colleagues, no difference in the complete response rate or interim progression-free survival was found...
